Company intelligence / Profile preview

Cytos Biotechnology AG

Schlieren, Zurich, Switzerlandethz.ch ↗

Ownership: Private
Development stage: Commercial

Overview

Cytos Biotechnology developed targeted immunotherapies, with its lead candidate CYT003 reaching Phase 2b clinical trials for asthma. The company demonstrated that CYT003 could maintain asthma control and lung function after withdrawal of standard therapy, with a good safety profile in over 450 patients. In January 2016, the company merged with Kuros Biosurgery Holding Ltd., was renamed Kuros Biosciences Ltd., and ceased to exist as an independent entity[5][6].

Therapeutic areas: PulmonologyImmunology
Modalities: ImmunotherapiesVirus-like particles (VLPs)Oligonucleotide-based therapeutics
Industry: Biotech

Partnerships

Arbutus Biopharma Corp. – exclusive license for VLP platform in hepatitis B treatment/prevention.Checkmate Pharmaceuticals LLC – exclusive license for oncology applications using VLP platform and CYT003-related technology.[6]

Beyond the preview

Go deeper on Cytos Biotechnology AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytos Biotechnology AG.

Explore the full profile